Physician profile
Rene Badillo
NPI 1487651741
$16,275.73
in general payments reported to CMS, 2019-2025
42 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,572 · 2020: $2,391 · 2021: $3,425 · 2022: $2,251 · 2023: $1,701 · 2024: $1,397 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,637.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,459.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,941.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,891.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,554.17 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,298.18 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $1,235.74 | 2019-2025 | |
| Astellas Pharma US INC | $884.85 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $662.33 | 2021-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Amgen INC. | $612.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $537.24 | 2019-2023 | |
| Abbvie INC. | $374.09 | 2021-2025 | Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $359.34 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $313.74 | 2019-2025 | Ajovy |
| Merck Sharp & Dohme LLC | $252.15 | 2019-2025 | Capvaxive, Gardasil 9 |
| Eisai INC. | $202.02 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Badillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.